The in vitro activity of sparfloxacin, a new quinolone, was compared with those of ciprofloxacin and fleroxacin against gram-positive and gram-negative bacteria, >90% of which were isolated from blood culture specimens of cancer patients. Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus, Enterobacter species, Escherichia coli, Kiebsiella species, Proteus vulgaris, and Serratia marcescens (inhibiting >90% of these isolates at a concentration of 0.5 ,ig/ml) and moderately active against Pseudomonas species, other Proteus species, and Citrobacterfreundii. Sparfloxacin inhibited >90% of staphylococci (including methicillin-resistant and coagulase-negative strains) at a concentration of 0.12 ,ig/ml and >90% of streptococci (including Streptococcus pneumoniae) at a concentration of 1.0 ,ug/mI. It was also active against Bacillus cereus, Enterococcus species, and Corynebacterium jeikeium, organisms that have become fairly common in cancer patients.
New quinolones, such as norfloxacin, ciprofloxacin, and ofloxacin, are currently being used for both prophylaxis and therapy of infections in neutropenic cancer patients (1-6, 9, 14, 16) . They are active against most gram-negative pathogens, but their activity against gram-positive organisms, particularly Streptococcus and Enterococcus species, is inadequate. The prophylactic use of 4-quinolones in patients with leukemia has resulted in a decrease in the number of documented gram-negative infections (5, 6, 16) . The use of these agents, however, either has had no effect on grampositive infections or has occasionally led to an increase in such infections (2) . Newer 4-quinolones that are active against commonly occurring gram-negative and gram-positive pathogens are therefore desirable. Sparfloxacin (CI-978; AT-4140) is a new [5- amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid] quinolone that is reported to have a broad antibacterial spectrum (7, 11) . We compared its in vitro activity to those of ciprofloxacin and fleroxacin.
The antimicrobial agents were obtained in the form of standard powders for laboratory use (14) Ciprofloxacin Fleroxacin 90% of isolates being susceptible to a concentration of 0.5 ,ug/ml. Sparfloxacin had moderate activity against Pseudomonas spp., including Pseudomonas aeruginosa, Pseudomonas putida, and Pseudomonas fluorescens, and against Xanthomonas maltophilia, with MICs ranging from 0.06 to 4.0 ,ug/ml and with an MIC for 90% of the isolates of 2.0 ,ug/ml. Haemophilus influenzae isolates were extremely susceptible to sparfloxacin. The MICs for 90% of the strains tested were lower than those of ciprofloxacin for Acinetobacter spp. and Morganella morganii; equal to those of ciprofloxacin for Aeromonas hydrophila, Alcaligenes denitrificans subsp. xylosoxidans, Enterobacter spp., Escherichia coli, Klebsiella spp., and Salmonella spp.; and higher than those of ciprofloxacin for Citrobacter spp., Pseudomonas spp. (including P. aeruginosa), Proteus mirabilis, and Serratia marcescens. Against most gram-negative isolates, the MICs of sparfloxacin for 90% of the isolates tested were either equal to or 2-to 8-fold lower than those of fleroxacin. Against gram-positive organisms such as Staphylococcus aureus, including methicillin-resistant strains, coagulasenegative Staphylococcus spp., Enterococcus spp., and Streptococcus spp. (including Streptococcus pneumoniae), the MICs of sparfloxacin for 90% of the strains tested were 2-to 16-fold lower than those of ciprofloxacin and fleroxacin. Sparfloxacin was also active against Bacillus cereus and Corynebacterium jeikeium isolates. All three quinolones were active against the majority of isolates that were resistant to other agents (amikacin, ceftazidime, piperacillin; data not shown) commonly used at our institution, indicating a lack of cross resistance. The MBCs of sparfloxacin against selected gram-negative and gram-positive isolates were equal to or twofold higher than the MICs, as were those of ciprofloxacin and fleroxacin, indicating good bactericidal activity (Table 2 ). These data are consistent with those of Kojima et al. (7) .
Among the quinolones currently approved for clinical use in this country, ciprofloxacin appears to be the most active. It has been used successfully for a variety of serious infections, including those in neutropenic cancer patients (1, 3, 14) . Its usage, along with that of other quinolones, has been shown to be partially responsible for the increase in gram- 1490, 1988) . This was significantly longer than the half-life of ciprofloxacin (3.3 to 5.0 h) and fleroxacin (10 h) and might make once-a-day administration of sparfloxacin possible, whereas most currently used quinolones need to be administered twice or three times a day. Pharmacokinetics in animals also suggest good tissue penetration and a long half-life in plasma and tissues (10) . Further in vitro, pharmacokinetic, and toxicological studies with sparfloxacin are needed. If they prove to be favorable, sparfloxacin could become a useful new quinolone and would deserve to be evaluated in clinical trials.
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